Advances in Treating GEP-NETs

CE / CME

Expert Insights on New Advances in the Treatment of Gastroenteropancreatic NETs

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: December 30, 2024

Expiration: December 29, 2025

Activity

Progress
1 2
Course Completed

References

  1. Pavel M, Öberg K, Falconi M; ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844-860.
  2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335-1342.
  3. Hope TA, Pavel M, Bergsland EK. Neuroendocrine tumors and peptide receptor radionuclide therapy: when is the right time? J Clin Oncol. 2022;40:2818-2829.
  4. McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671.
  5. Klimstra. WHO Classification of Tumours of the Digestive System. 2010;322.
  6. Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
  7. Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420-425.
  8. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377-383; discussion 384-385.
  9. Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981;90:720-728.
  10. Ratnayake GM, Laskaratos FM, Mandair D, et al. What causes desmoplastic reaction in small intestinal neuroendocrine neoplasms? Curr Oncol Rep. 2022;24:1281-1286.
  11. Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28:749-756.
  12. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275.
  13. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68:471.
  14. Delle Fave G, O’Toole D, Sundin A, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016;103:119-124.
  15. Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol. 2011;18:2826-2832.
  16. Lee L, Ramos-Alvarez I, Ito T, et al. Insights into effects/risks of chronic hypergastrinemia and lifelong PPI treatment in man based on studies of patients with Zollinger-Ellison syndrome. Int J Mol Sci. 2019;20:5128.
  17. Mohamed A, Wu S, Hamid M, et al. Management of appendix neuroendocrine neoplasms: insights on the current guidelines. Cancers (Basel). 2022;15:295.
  18. Maione F, Chini A, Milone M, et al. Diagnosis and management of rectal neuroendocrine tumors (NETs). Diagnostics (Basel). 2021;11:771.
  19. Gallo C, Rossi RE, Cavalcoli F, et al. Rectal neuroendocrine tumors: current advances in management, treatment, and surveillance. World J Gastroenterol. 2022;28:1123-1138.
  20. Naunheim KS, Zeitels J, Kaplan EL, et al. Rectal carcinoid tumors—treatment and prognosis. Surgery. 1983;94:670-676.
  21. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656.
  22. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224.
  23. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
  24. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005.
  25. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514.
  26. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968.
  27. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501.
  28. Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41:1359.
  29. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.
  30. Strosberg J, El-Haddad G, Wolin E, et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.
  31. Kunz PL, Benson AB, Bodei L, et al. The phase 3 NETTER-1 study of 177LuDOTATATE in patients with midgut neuroendocrine tumors: updated progression-free survival analyses. Presented at: 2021 North American Neuroendocrine Tumor Society. 2021. Abstract 142.
  32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. v.2.2024. nccn.org. Accessed December 26, 2024.
  33. Strosberg JR, Al-Toubah T, Pellè E, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62:69-72.
  34. Al-Toubah TE, Pelle E, Strosberg JR. Risk of myelodysplastic syndrome/acute leukemia with sequential capecitabine/temozolomide and 177Lu-dotatate. J Clin Oncol. 2022;40(4 suppl):513-513.
  35. Hope TA, Bodei L, Chan JA, et al. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:222-227.
  36. Porta C, Calvo E, Climent MA, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol. 2012;61:826-833.
  37. Al-Toubah T, Morse B, Strosberg J. Efficacy of capecitabine and temozolomide in small bowel (midgut) neuroendocrine tumors. Curr Oncol. 2022;29:510-515.
  38. Kanabar R, Barriuso J, Mairéad G, et al. Liver embolisation for patients with neuroendocrine neoplasms: systematic review. Neuroendocrinology. 2021;111:354-369.
  39. Kim HJ, Lee SH, Shim HJ, et al. Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1265240.
  40. Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19:390.
  41. Braat MN, Samim M, van den Bosch MA, et al. The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016;4:283-295.
  42. Qian ZR, Li T, Ter-Minassian M, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45:1386-1393.
  43. Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34:3906.
  44. Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28:339.
  45. Baudin E, Walter TA, Beron A, et al. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial. Presented at: 2022 European Society for Medical Oncology Congress; September 9-13, 2022. Abstract 8870.
  46. Salazar R, Tafuto S, Krogh M, et al.Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206) Ann Oncol. 2022;33:S1412.
  47. Bourdeleau-Guerry PA, Pokossy Epee JB, Hentic OB, et al. Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumors (PanNETs): frequency, prognostic impact, and causal factors. Presented at: 21st Annual European Neuroendocrine Tumor Society Conference; March 13-15, 2024. Abstract F02.
  48. de Mestier LA, Cohen DA, de Rycke OB, et al. Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well-differentiated pancreatic neuroendocrine tumors. Presented at: 21st Annual European Neuroendocrine Tumor Society Conference; March 13-15, 2024. Abstract I09.
  49. Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086-1092.
  50. Pritzl SL, Kusne Y, Halfdanarson TR, et al. Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-dotatate. Leuk Res. 2024;136:107434.
  51. Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807-2817.
  52. US Food and Drug Administration. FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets. Accessed December 26, 2024.
  53. Lutetium Lu 177 dotatate injection, for intravenous use [prescribing information]. East Hanover, NJ: Novartis; 2024.
  54. Lee CH, Voss MH, Carlo MI, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. 2022;40:2333-2341.
  55. Chan J, Geyer S, Ou FS, Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann Oncol. 2024;34:S1292.